Target- |
MechanismMagnetic resonance imaging enhancers |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.US |
First Approval Date08 Dec 1999 |
100 Clinical Results associated with Mallinckrodt Deutschland GmbH
0 Patents (Medical) associated with Mallinckrodt Deutschland GmbH
100 Deals associated with Mallinckrodt Deutschland GmbH
100 Translational Medicine associated with Mallinckrodt Deutschland GmbH